Impact Partnership Wealth LLC purchased a new position in The Clorox Company (NYSE:CLX - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,151 shares of the company's stock, valued at approximately $464,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Diversify Advisory Services LLC grew its holdings in shares of Clorox by 13.9% in the first quarter. Diversify Advisory Services LLC now owns 1,913 shares of the company's stock worth $270,000 after purchasing an additional 233 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in Clorox in the first quarter worth $1,546,000. Independent Wealth Network Inc. lifted its stake in Clorox by 12.1% in the first quarter. Independent Wealth Network Inc. now owns 4,778 shares of the company's stock worth $704,000 after acquiring an additional 514 shares during the period. Retirement Planning Co of New England Inc. lifted its stake in Clorox by 138.3% in the first quarter. Retirement Planning Co of New England Inc. now owns 11,070 shares of the company's stock worth $1,630,000 after acquiring an additional 6,425 shares during the period. Finally, Forum Financial Management LP purchased a new position in Clorox during the first quarter valued at $254,000. 78.53% of the stock is owned by hedge funds and other institutional investors.
Clorox Stock Performance
Shares of NYSE:CLX traded up $1.29 during trading on Wednesday, reaching $131.07. The company had a trading volume of 390,963 shares, compared to its average volume of 1,424,565. The firm has a market capitalization of $16.15 billion, a price-to-earnings ratio of 23.56, a price-to-earnings-growth ratio of 3.33 and a beta of 0.51. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44. The stock's fifty day moving average price is $127.36 and its 200 day moving average price is $141.06. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37.
Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company's revenue was down 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS. As a group, equities research analysts predict that The Clorox Company will post 7.15 EPS for the current year.
Insider Transactions at Clorox
In related news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the transaction, the director directly owned 4,000 shares of the company's stock, valued at $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. Citigroup restated a "neutral" rating and set a $135.00 price objective (down from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. Wells Fargo & Company decreased their target price on Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 9th. Morgan Stanley decreased their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Finally, UBS Group decreased their target price on Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research report on Thursday, July 17th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $145.17.
Get Our Latest Stock Report on CLX
About Clorox
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Featured Articles

Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.